Publication
PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer.
Guimei Yang, Huixia Dou, Liting Xue, Weijie Chen, Yao Guo, Grace Xue, Ying Sun, Hanxiao Shi, Jian Li, Jianing Song, Zhen Li, Congjun Zhang, Renhong Tang, Feng Zhou
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Protein arginine methyltransferase 5 (PRMT5) is a critical therapeutic target in cancer. In this study, we report SCR-6920, a potent and selective oral PRMT5 inhibitor characterized by a substrate-competitive binding mode to PRMT5:methylosome protein 50 with high affinity. SCR-6920 shows broad…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available